Drug Trial Radar · NCT06002555
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
May 23, 2023
Primary completion
Sep 22, 2023
Study completion Sep 22, 2023
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 67 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial compares the relative bioavailability of apraglutide in dual-chamber syringes (DCS) versus the reference formulation apraglutide in vials.
Conditions
- Healthy Subjects
Interventions
ApraglutideDrug
Peptide analogue of GLP-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma apraglutide primary PK parameter: Maximum observed plasma concentration (Cmax)Time frame: 0 to 312 hours post dose in each period
- Plasma apraglutide primary PK parameter: AUCinf or AUClastTime frame: 0 to 312 hours post dose in each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Clinical Research Unit
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.